Alentis Therapeutics AG

3 results · Page 1 of 1

Swipe the table sideways for more columns.

Trial	Conditions	Status	Phase	Updated	NCT ID
Rescue of Nephrons With ALE.F02 (RENAL-F02)	Glomerulonephritis Rapidly Progressive	Recruiting	Phase 2	2026-08-14	NCT06047171
A Study to Investigate ALE.P03 as Monotherapy in Adult Patients With Selected Advanced or Metastatic CLDN1+ Solid Tumors	Digestive System Diseases, Digestive System Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, adenocarcinoma, carcinoma, cervical squamous cell carcinoma, cholangiocarcinoma, colonic disorder, colorectal cancer, colorectal neoplasm, digestive system disorder, digestive system neoplasm, epithelial neoplasm, intestinal disorder, intrahepatic cholangiocarcinoma, neoplasm, rectal disorder, transitional cell carcinoma, urothelial carcinoma	Recruiting	Phase 1 / Phase 2	2026-07-02	NCT07169734
A Study to Investigate ALE.P02 as Monotherapy in Adult Patients With Selected CLDN1+ Solid Tumors	Digestive System Diseases, Digestive System Neoplasms, Esophageal Neoplasms, Head and Neck Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, carcinoma, cervical squamous cell carcinoma, digestive system disorder, digestive system neoplasm, epithelial neoplasm, esophageal disorder, esophageal squamous cell carcinoma, head and neck squamous cell carcinoma, neoplasm, squamous cell carcinoma, squamous cell neoplasm	Recruiting	Phase 1 / Phase 2	2026-06-29	NCT06747585

Clinical trials